Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023GlobeNewsWire • 08/01/23
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's DiseaseGlobeNewsWire • 07/17/23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) 2023GlobeNewsWire • 07/16/23
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023GlobeNewsWire • 06/13/23
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/09/23
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare ConferenceGlobeNewsWire • 05/04/23
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023GlobeNewsWire • 05/02/23
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer's DiseaseGlobeNewsWire • 03/28/23
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business HighlightsGlobeNewsWire • 03/27/23
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023GlobeNewsWire • 03/20/23
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer's DiseaseGlobeNewsWire • 02/13/23
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of DirectorsGlobeNewsWire • 01/04/23
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/15/22
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/14/22